Shandong Buchang Pharmaceuticals Co., Ltd.

SHSE:603858 Stock Report

Market Cap: CN¥16.8b

Shandong Buchang Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chao Zhao

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentagen/a
CEO tenure23.9yrs
CEO ownershipn/a
Management average tenure14.9yrs
Board average tenure12.8yrs

Recent management updates

Recent updates

Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?

Dec 31
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?

Investors Aren't Buying Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues

Dec 04
Investors Aren't Buying Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Aug 26
The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Jul 29
Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Apr 27
Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Feb 28
We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

CEO

Chao Zhao (57 yo)

23.9yrs

Tenure

CN¥2,439,600

Compensation

Mr. Chao Zhao serves as the President and Director of Shandong Buchang Pharmaceutical Co., Ltd. since 2001 and served as its General Manager since 2001. Mr. Zhao serves as Executive Director and General Ma...

Leadership Team

NamePositionTenureCompensationOwnership
Chao Zhao
President & Director23.9yrsCN¥2.44mno data
Yi Min Wang
Executive VP & Vice Chairman12.8yrsCN¥2.16mno data
Ren Hui Xue
VP of Marketing & Director14.9yrsCN¥2.12mno data
Xifang Wang
Chief Engineer7.8yrsCN¥1.11mno data
Xiao Ping Pu
VP of Securities13.9yrsCN¥1.40mno data
Zhao Buchang
Founderno datano datano data
Bao Cai Wang
CFO & Director14.9yrsCN¥931.30kno data
Kai Cheng
Accounting Supervisorno datano datano data
Haiqin Wu
Chairman of the Academic Committeeno datano datano data
Wei Zhao
Vice President of Procumentno datano datano data

14.9yrs

Average Tenure

62yo

Average Age

Experienced Management: 603858's management team is seasoned and experienced (14.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chao Zhao
President & Director23.9yrsCN¥2.44mno data
Yi Min Wang
Executive VP & Vice Chairman12.8yrsCN¥2.16mno data
Ren Hui Xue
VP of Marketing & Director12.8yrsCN¥2.12mno data
Xiao Ping Pu
VP of Securities12.8yrsCN¥1.40mno data
Bao Cai Wang
CFO & Director12.8yrsCN¥931.30kno data
Yu Gao
Director12.8yrsCN¥190.50kno data
Tao Zhao
Chairman of the Board of Directors23.9yrsno data53.83%
CN¥ 9.1b
Jing Zhao
Vice Chairman of the Board12.8yrsCN¥1.45mno data
Ya Feng Wang
Director12.8yrsCN¥190.50kno data
Chun Yi Li
Director12.8yrsCN¥190.50kno data
Hua Cheng
Independent Director3.5yrsCN¥190.50kno data
Ming Geng Wang
Chairman of the Supervisory Board12.8yrsno datano data

12.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 603858's board of directors are seasoned and experienced ( 12.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 17:29
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Buchang Pharmaceuticals Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.